Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330108 | 0.93 | MAPK14 (0.69) | MAPK14LMNAHSP90AA1RAB9ASMN1; SMN2 | |
| SCHEMBL4330121 | 0.91 | MAPK14 (0.64) | MAPK14HSP90AA1RAB9A | |
| SCHEMBL4336205 | 0.84 | MAPK14 (0.70) | MAPK14LMNAHSP90AA1HPGD | |
| SCHEMBL4332006 | 0.84 | MAPK14 (0.70) | MAPK14LMNARAB9ASMN1; SMN2HPGD | |
| SCHEMBL4331928 | 0.83 | MAPK14 (0.67) | MAPK14LMNASMN1; SMN2HPGD | |
| SCHEMBL4334761 | 0.83 | MAPK14 (0.54) | MAPK14HSP90AA1 | |
| SCHEMBL4335478 | 0.83 | MAPK14 (0.68) | MAPK14HSP90AA1RAB9ASMN1; SMN2 | |
| SCHEMBL4334980 | 0.82 | MAPK14 (0.88) | MAPK14LMNASMN1; SMN2 | |
| SCHEMBL4482965 | 0.82 | MAPK14 (0.68) | MAPK14LMNAHSP90AA1RAB9ASMN1; SMN2 | |
| SCHEMBL4341309 | 0.82 | MAPK14 (0.77) | MAPK14LMNAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885LMNA 4792/4885HSP90AA1 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.